The Prevalence of Renal Failure
Results from the German Health Interview and Examination Survey for Adults, 2008–2011 (DEGS1)
; ; ; ;
Background: The prevalence of non–end stage renal failure among adults in Germany is unknown. Accurate figures would enable us to estimate the overall need for kidney replacement therapies and the unexploited potential for disease prevention. Renal failure is also an important cardiovascular risk factor. Until now, American prevalence figures have often been applied to Germany despite dissimilarities between the two populations.
Methods: We analyzed data on renal function from the nationwide German Health Interview and Examination Survey for Adults, 2008–2011 (DEGS1), which was carried out by the Robert Koch Institute. The glomerular filtration rate was estimated (eGFR) from the serum creatinine and cystatin C levels (CKD-EPI formula) and a semiquantitative measure of albuminuria. Relationships between renal failure and its possible determinants were quantified with adjusted prevalence ratios (PR) and 95% confidence intervals (95% CI).
Results: Roughly 2.3% (95% CI: [1.9; 2.6 ]) of persons aged 18–79 had an eGFR below 60 mL/min/1.73 m2. The prevalence rose with age. We extrapolated these figures conservatively to persons aged 80 and above, who were not included in the DEGS1, and arrived at a figure of at least 2 million persons in Germany with renal failure. 11.5% of the population have albuminuria of at least 30 mg/L. Diabetes mellitus (PR = 2.25, 95% CI: [1.59; 3.16]) and arterial hypertension (PR = 3.46, 95% CI: [1.95; 6.12]) are important determinants.
Conclusion: This study provides the first representative estimate of the prevalence of renal failure in Germany. The condition is highly dependent on age but less prevalent than previously assumed on the basis of American prevalence figures.
Approximately 80 000 patients with end stage renal disease (ESRD) are treated in Germany with hemodialysis or peritoneal dialysis (1). Additionally, about 23 000 people are in follow-up after a successful kidney transplant. Medical care for both patient groups is extremely costly. The vast majority of patients who require long-term dialysis treatment were previously afflicted with progressive chronic kidney disease (CKD). However, permanently requiring renal replacement therapy is just one of the serious consequences of CKD. For instance, non–dialysis-dependent patients with a reduced glomerular filtration rate (GFR) have a stage-dependent, 1.4-fold to 18.6-fold increase of overall mortality (2). Indeed, patients with a GFR <60 mL/min/1.73m2 are more at risk for death—with a more than two-fold increase (45.7% in 5 years)—than for requiring renal replacement therapy due to disease progression (19.9%) (3).
There are currently no population-based estimates for Germany about the prevalence of chronic renal dysfunction in the non–dialysis-dependent stage. Such studies are particularly necessary for effectively planning and carrying out preventive measures, as well as for providing a continuation of medical care for ESRD. Whether epidemiological data from the United States population—such as that of the National Health and Nutrition Examination Survey (NHANES), which found a population-wide prevalence of 8% for reduced eGFR (4)—can be transferred to the German population is questionable, not the least because of differences in ethnic composition. Worldwide, data are very heterogeneous and difficult to compare, mainly due to differences in measurement methods (5).
The population-representative “German Health Interview and Examination Survey for Adults” (DEGS1) (6) is part of nationwide continuous health monitoring, carried out by the Robert Koch Institute (RKI) on behalf of the German Federal Ministry of Health. The most recent data collection in DEGS (DEGS1), conducted from 11/2008 to 12/2011, included 7115 women and men aged 18 to 79 years. Within the DEGS1 framework, renal function parameters were determined, and participants answered questions about renal dysfunction and any treatment for it. Based on data analyses, we were able to establish a population-representative estimate for the prevalence of renal dysfunction in adults in Germany, as well as determine any correlations between renal dysfunction and age, sex, and known risk factors. Furthermore, we were able to assess the levels of awareness about renal dysfunction and the medical treatment received for it.
Participants and survey methodology
The complex design of the DEGS survey wave 2008–2011 (DEGS1) has been described in detail (6, 7). The study population was selected to be representative of the total adult resident population, aged 18 to 79 years, in Germany. Overall, 7115 participants were examined in one of the 180 study centers. To determine socio-demographic variables, information was collected about education levels, vocational training, employment status, and net household income. Participants were categorized as having a low, medium, or high socioeconomic status (SES) (8).
Information on diabetes, hypertension, and smoking status
The survey methodology for diabetes mellitus (9), arterial hypertension (10), and smoking status (11) have been published (see details in the eSupplement). Deviating from the above-mentioned definition (9), cases of gestational diabetes were not included for prevalence estimation.
Evaluation of kidney function
To determine kidney function, measurements were taken from participant blood samples for standardized serum creatinine concentration (Architect, Abbott Diagnostics, Wiesbaden; IDMS traceable creatinine assay) and for cystatin C (Prospec, Siemens Healthcare, Eschborn). The estimated GFR (eGFR) was calculated using the CKD-EPI equation for creatinine and cystatin C (12). Following recommendations of the Kidney Disease Improving Global Outcomes Initiative (KDIGO) (13), eGFR values were categorized as reduced at <60 mL/min/1.73 m2. Urinary albumin was determined from a random urine sample by semi-quantitative test strips (Micral, Roche Diagnostics, Grenzach-Wyhlen). However, results from the Micral test strips have limited diagnostic accuracy and are categorized in ranges (negative, 20 mg/L, 50 mg/L, and 100 mg/L) that are not congruent with albumin/creatinine ratio measurements or with the KDIGO-recommended albuminuria categories (A1, <30 mg/g; A2, 30 to 300 mg/g; A3, >300 mg/g) (13). For this reason, participant results were reclassified according to Parikh (14), taking into account the Micral test false- and true-positive rates of determining albuminuria as compared to the KDIGO categories. Moreover, a diagnosis of increased albumin excretion usually requires repeated albuminuria measurements (4, 13), which was not carried out in the DEGS1 framework. Therefore, to estimate the prevalence of persistent albuminuria, an eGRF-independent correction was made similar to that described by Coresh (4); for correction details, see the eSupplement.
All analyses were statistically weighted to correct for deviations in the sample from the German population (as of 31 December 2010) with respect to age, sex, region, nationality, community type, and education levels. For the DEGS1 subgroup who had already participated in the German Federal Health Survey 1998, calculation of the individual weighting factor also considered the re-participation probability (6). To account for the association between impaired kidney function and the risk factors of smoking, diabetes mellitus, and arterial hypertension, adjusted prevalence ratios (PR) and 95% confidence intervals (95% CI) were estimated using log-binomial regression models (15). Adjustment variables were determined using directed acyclic graphs (16). All analyses were performed with SAS version 9.3 (Cary, NC). To take into account both the weighting and the correlation of the participants within a community, all confidence intervals were calculated using the survey procedures of SAS.
The prevalence of eGFR <60 mL/min/1.73m2 for adults aged 18 to 79 years is 2.3% (95% CI: [1.9; 2.6]). This estimate is based on the survey of 7115 participants, whose demographics are shown in Table 1. Renal dysfunction was associated primarily with increasing age (see Figure). The estimate was based on an eGFR calculated with the CKD-EPI equation using creatinine and cystatin C. This can be considered reliable especially for values around GFR 60 mL/min/1.73m2. However, the more widely used Modification of Diet in Renal Disease (MDRD) Study formula (17) estimated a higher prevalence of renal dysfunction, of 3.5% (95% CI, 3.1 to 3.9).
Increased urinary albumin excretion is also a sign of renal injury. Albuminuria can be seen together with a reduced GFR, but it also occurs by itself and as an early sign of renal microvascular damage. The prevalence of albuminuria ≥ 30 mg/L was determined with respect to age and sex (eTable 1) as well as for renal impairment (Table 2).
Known factors that influence the occurrence of chronic renal dysfunction are diabetes mellitus (adjusted PR = 2.25) and arterial hypertension (adjusted PR = 3.46). Moreover, former smokers had slightly increased prevalence ratios for renal dysfunction (Table 3).
Only about 28% of participants with an eGRF of <60 mL/min/1.73m2 were aware of their impaired kidney function (Table 4). Of those who were aware, only about two-thirds reported that they receive medical treatment for kidney disease. Thus, compared to the limitations of the measurement-based eGFR, self-reports of chronic renal dysfunction are highly specific but less sensitive. Self-awareness of renal dysfunction was not associated with socioeconomic status or sex (Table 3).
Approximately 2.3% of the adult German population, aged 18 to 79 years, has an eGFR of <60 mL/min/1.73m2. In the same group, the estimated overall prevalence for elevated urinary albumin excretion is 11.5%, while that for having either a reduced eGFR or albuminuria is 12.7%. Based on these data, we are able for the first time to quantitatively estimate the prevalence of kidney damage in Germany. While the medical care requirements for patients with end-stage kidney failure who require renal replacement therapy is known, due to the established quality assurance systems (1), the percentage of people in non–dialysis-dependent stages could previously only be roughly estimated based US surveys (4). Data was available for Germany only for people aged 70 years or older from the Berlin Initiative study (BIS) (18), which determined that 30.1% of this age group have an eGFR of <60mL/min/1.73 m2.
The prevalence estimates mean that, in Germany in 2011, about 1.53 million adults in the age group 18 to 79 years had a reduced eGFR. Further, the data show a strong association with age. Thus, while kidney damage is very rare in people younger than 50 years of age, every eighth person aged 70 to 79 years is affected. While it can be assumed that this prevalence is even higher in the over-80s age group, the present survey can not draw any conclusions about this. A very conservative estimate would assume that the prevalence of reduced eGFR observed for the 70- to 79-year-olds remains the same for the over-80s. Based on this assumption, at least 2 million people in Germany have an eGFR of <60 mL/min/1.73m2. However, depending on the actual prevalence in the over-80s group, the overall prevalence could reach up to 2.5 million. The Berlin Initiative Study reported that 20.7% of the 70- to 79-year-old participants, and 46.6% of the ≥ 80-year-old participants, had a reduced eGFR (18). These figures were calculated using the CKD-EPIKrea equation, which classifies fewer participants as having renal insufficiency (12).
Nevertheless, our prevalence estimates are lower than those estimated based on the US NHANES results. In contrast to DEGS1, the survey population in NHANES also included individuals older than 79 years (7.4% of the total) and was heterogeneous in terms of ethnic composition. The high diversity of populations represented in NHANES is particularly striking (weighted percentage: 72.6% non-Hispanic white, 10.5% non-Hispanic blacks, 7.3% Hispanic, and 1.2% other). In particular, non-Hispanic blacks, but also other non-white populations, are much more frequently affected with diabetes mellitus (19). Additionally, when diabetes or arterial hypertension is present, these groups often have higher cardiovascular and renal risks (20), and they often have impaired kidney function (4). DEGS1 defined the representative population to be those reported at the local resident registries during the survey period, of people whose primary residence was in Germany and who were 18 to 79 years old, irrespective of origin or nationality (7). As adults without German nationality were oversampled by a factor of 1.5 (6), the proportion of people with an immigrant background after weighting was around 20%, which is not negligible (21). However, population-representative statements for this group as a whole, or even for different subgroup ethnicities, can not be made due to the survey design.
As directly measuring GFR is complicated, the empirical estimation, eGFR, is routinely used instead in epidemiological surveys as well as in everyday clinical practice. Here, we have used the CKD-EPI equation (12) to estimate the parameters for serum creatinine, serum cystatin C, age, sex, and ethnicity. The MDRD equation used in NHANES (17) has been criticized for its inaccuracy in eGFR values of >60 mL/min/1.73m2 (22). The CKD-EPI equation is more reliable, and particularly so within this range (23, 24).
Calculating the DEGS1 prevalence with the MDRD equation gives a higher overall prevalence. Modeling calculations on other populations show that 17% to 22% of the participants would be reclassified to the healthier GFR category (e.g., eGFR <60 to eGFR ≥ 60 mL/min/1.73m2) if the CKD-EPI equation, rather than the MDRD equation, is used. In contrast, there were few reclassifications in individuals with severely imparied renal function (25–27). Participants who were classified by the MDRD equation to have renal insufficiency, and by the CKD-EPI equation to have an eGFR >60 mL/min/1.73m2, would have a significantly better renal and cardiovascular prognosis than the non-reclassified participants (27). This suggests that classification based on the CKD-EPI equation avoids a falsely high prevalence estimate of renal insufficiency. Calculating the eGFR by the CKD-EPI equation, which takes into account creatinine and cystatin C, is also the method of choice according to the KDIGO guidelines (13).
The nature of the cross-sectional design of DEGS1 does not allow conclusions to be drawn about the permanency of a dysfunction. According to the definition of chronic kidney disease (13), detection of a structural or functional disruption over a period of at least three months is required to be termed chronic. For this reason, we discuss here “impaired kidney function” rather than chronic kidney disease (CKD); however, the probability is low that people with acute renal failure were included as DEGS1 participants.
Increased urinary albumin excretion (30–300 mg/g creatinine; formerly termed “microalbuminuria”) is also a symptom of renal damage and can be found as an early sign of diabetic or hypertensive damage. The presence of albuminuria with impaired kidney function is associated with a faster progression of renal damage (28). Albuminuria is additionally associated with an increased risk of cardiovascular events (29).
The ability to estimate the albuminuria prevalence was hindered in both NHANES and DEGS1 by the fact that the surveys were conducted with only limited validity, due to practical restraints. Specifically, the KDIGO definition of albuminuria (13) requires elevated urinary albumin excretion from at least two independent samplings. However, both surveys were conducted only once. This leads to an overestimation of persistent albuminuria, an effect that can be mathematically corrected (30). Albumin excretion was measured by quantifying the albumin/creatinine ratio in NHANES, but only by semi-quantitative (test strips) in DEGS1. The predictive value of this test strip for the actual presence of albuminuria is known (14), so that this can also be mathematically corrected. The 12.7% prevalence of renal damage symptoms (reduced eGFR and/or albuminuria) in the surveyed age range allows us to assume that more than 10 million adults (including those aged 80 years and over) are affected in the population residing in Germany.
People with renal insufficiency not only are in danger of renal function deterioration and long-term dialysis dependency, but also from an increased risk of death. In large population-based surveys, the age-standardized mortality steadily increases with decreasing GFR. For instance, 0.76 deaths/100 person-years is observed in populations with GFR ≥ 60 mL/min/1.73m2, but this increases to 11.36 deaths/100 person-years once the GFR has reached 15–30 mL/min/1.73m2, and 14.14 deaths/100 person-years at GFR < 15 mL/min/1.73m2 (2). Similarly, the risk of cardiovascular events increases significantly with decreased GFR. Albuminuria provides a comparable index with additive importance—doubling of the urinary albumin concentration is associated with a 35% increased risk of death (31). Even the urinary albumin levels that fall within what has been considered as a “normal” range of excretion (<30 mg/g creatinine) are clearly associated with overall and cardiovascular mortality (32).
Diabetes mellitus and arterial hypertension are important predictors of kidney function impairment. As might be expected, these two diseases numerically represent the most important causes of long-term dialysis treatment (1). Based on the DEGS1 data, we are now able to provide a quantitative estimate of the relationship between these factors and the prevalence of kidney function impairment for the general population in Germany. In patient collectives with renal insufficiency, nicotine is known to increase the risk of progression for diabetic (33) and non-diabetic (34) kidney damage. The DEGS1 cross-sectional study did not reveal an association between nicotine use and prevalence of a reduced eGFR.
Critically, this study reveals that people with impaired kidney function are often unaware of their status. Approximately three-fourths of the participants with eGFR <60 mL/min/1.73m2 claimed to have no knowledge of any kidney damage. Among those who were aware of their renal dysfunction, only two-thirds reported that they received medical treatment. Taken together, these results reveal that only about 16% of those affected receive appropriate medical care. From the perspective of medical care providers, these figures are highly relevant. For instance, taking adequate preemptive measures for health disorders such as chronic renal insufficiency requires the highest possible level of information about those affected. Preventive measures—such as cause identification, treatment of inflammatory kidney diseases, reduction of blood pressure, optimization of metabolic control, drug-induced angiotensin blockade, and avoidance of nephrotoxic effects—are strongly dependent on the cooperation of patients.
In summary, evaluation of DEGS1 data has provided the first estimates of a representative prevalence for renal impairment and/or albuminuria for the resident adult population (18 to 79 years old) in Germany. Kidney damage is inherently progressive, but deterioration can often be delayed therapeutically. Further, kidney impairment is a significant risk for cardiovascular disease. Knowing this prevalence rate is important for planning and organizing medical care for those affected, which goes far beyond planning for cost-intensive renal replacement therapy.
The authors thank Angelika Schaffrath Rosario of the Robert Koch Institute, Berlin, for helpful comments on the statistical analyses of the data.
Conflict of interest statement
Collection of DEGS1 data, on which this study was based, was funded by the nationwide health monitoring program of the Robert Koch Institute for the Federal Ministry of Health. The project in this report was funded by the KfH Foundation for Preventative Medicine (to Prof. Dr. Andreas Stang, MPH, Center for Clinical Epidemiology, Universitätsklinikum Essen, together with Prof. Dr. Matthias Girndt, Department of Medicine II, Martin Luther University, Halle-Wittenberg). Prof. Stang has received study support (third-party funds) from the Federal Ministry of Education and Research (BMBF) (grant number: 01ER1305). The responsibility for the content of this publication lies solely with the authors.
Prof. Girndt has received speaking fees from Baxter Inc, Amgen GmbH, Roche AG, and Hexal.
The remaining authors declare that no conflict of interest exists.
Manuscript received on 16 July 2015, revised version accepted on 24 September 2015.
Translated from the original German by Veronica A. Raker, PhD.
Prof. Dr. med. Andreas Stang, MPH
Leiter des Zentrums für Klinische Epidemiologie
Institut für Medizinische Informatik,
Biometrie und Epidemiologie
45147 Essen, Germany
N Engl J Med 2012; 367: 20–9.
Nephrol Dial Transplant 2004; 19: 1881–5.
Clin Chem 2007; 53: 766–72.
J Am Soc Nephrol 2005; 16: 763–73.
a collaborative meta-analysis. Lancet 2010; 375: 2073–81.
Institute for Medical Epidemiology, Biometrics and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle (Saale): Dr. med. vet. Trocchi, MSE
Department of Epidemiology and Health Monitoring of the Robert Koch Institute, Berlin: Dr. med. Scheidt-Nave, MPH
Center for Clinical Epidemiology; Institute of Medical Informatics, Biometry and Epidemiology, University Hospital Essen: Prof. Dr. med. Andreas Stang, MPH
Department of Epidemiology, School of Public Health, Boston University, Boston, USA: Prof. Dr. med. Stang, MPH
Monitoring and management of chronic kidney disease in ambulatory care – analysis of clinical and claims data from a population-based studyBMC Health Services Research, 202210.1186/s12913-022-08691-y
Correct use of non-indexed eGFR for drug dosing and renal drug-related problems at hospital admissionEuropean Journal of Clinical Pharmacology, 202010.1007/s00228-020-02953-6
Deutsches Ärzteblatt international, 201610.3238/arztebl.2016.0505a
Acquired Comorbidities in Adults with Congenital Heart Disease: An Analysis of the German National Register for Congenital Heart DefectsJournal of Clinical Medicine, 202110.3390/jcm10020314
Acta Physiologica, 202110.1111/apha.13645
Eine chronische Niereninsuffizienz, auch in höherem Stadium, ist Patienten häufig unbekannt – aber warum wissen Frauen noch seltener von ihrer Erkrankung als Männer?DMW - Deutsche Medizinische Wochenschrift, 202210.1055/a-1819-0870
Health-Related Quality of Life according to Renal Function: Results from a Nationwide Health Interview and Examination SurveyKidney and Blood Pressure Research, 202210.1159/000518668
COVID-19 and Renal Failure — Adding Insult to Injury? Israel’s Experience Based on Nationwide Retrospective Cohort StudyJournal of General Internal Medicine, 202210.1007/s11606-022-07722-y
Incidence of Cardiovascular Events after Nephrectomy - A Single Centre, Matched Pair Analysis between Donor and Tumour Nephrectomy in a Long Term Follow-UpUrologia Internationalis, 201610.1159/000446248
Deutsches Ärzteblatt international, 201610.3238/arztebl.2016.0505b
Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie, 201910.1007/s40664-019-00377-3
Entwicklung von Qualitätsindikatoren für die Versorgung von Patient:innen mit chronischer NierenerkrankungBundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 202310.1007/s00103-023-03700-9
Tetralogy of Fallot or Pulmonary Atresia with Ventricular Septal Defect after the Age of 40 Years: A Single Center StudyJournal of Clinical Medicine, 202010.3390/jcm9051533
Deutsches Ärzteblatt international, 202010.3238/arztebl.2020.0745
Sicherheit und Effektivität der oralen Antikoagulation bei Vorhofflimmern und Niereninsuffizienz im PraxisalltagDMW - Deutsche Medizinische Wochenschrift, 202210.1055/a-1792-7094
Die Diabetologie, 202310.1007/s11428-023-01020-9
Deutsches Ärzteblatt international, 201610.3238/arztebl.2016.0506
Der Internist, 201910.1007/s00108-019-0598-3
Prevalence of Mental Disorders in a German Kidney Transplant Population: Results of a KTx360°-SubstudyJournal of Clinical Psychology in Medical Settings, 202210.1007/s10880-022-09861-0
Deutsches Ärzteblatt international, 202010.3238/arztebl.2020.0289
Dialyse aktuell, 202210.1055/a-1734-6806
Dialyse aktuell, 202210.1055/a-1857-7996
DMW - Deutsche Medizinische Wochenschrift, 202110.1055/a-1640-4503
Deutsches Ärzteblatt international, 201810.3238/arztebl.2018.0287
Deutsches Ärzteblatt international, 201610.3238/arztebl.2016.0083